For example and as expected, patients with higher stage cancers (stage II and III) were more likely to receive anthracycline (AC)–containing chemotherapy, whereas TC was more likely administered in women with estrogen receptor–positive tumors and lower stage tumors; the majority of women receiving AC-TC had triple-negative breast cancer. Here, ESR1 is linked to cancer.